ArticleScientific reports2018
Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 92 citations in OpenAlex.
- Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.Frontiers in immunology · 2019Trial
- IL-27 shapes NK cell heterogeneity and function in colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026Review
- Adoptive transfer of ILC2s reveals tumor homing in glioblastoma: a proof-of-concept study.Frontiers in oncology · 2026Article
- Macrophages regulate PD-1 and CTLA-4 expression on ILC2s and their responsiveness in the tumor microenvironment.Cellular & molecular immunology · 2025Article
- Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025Review
- The immune landscape in brain metastasis.Neuro-oncology · 2025Review
- Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.Cancers · 2024Review
- Article
- A diversity of novel type-2 innate lymphoid cell subpopulations revealed during tumour expansion.Communications biology · 2024Article
- A novel type-2 innate lymphoid cell-based immunotherapy for cancer.Frontiers in immunology · 2024Article
- Global research trends on innate lymphoid cells in the brain, gut and lung field: a bibliometric and visualized analysis.Frontiers in immunology · 2024Article
- Dendritic Cell Vaccines Impact the Type 2 Innate Lymphoid Cell Population and Their Cytokine Generation in Mice.Vaccines · 2023Article
- Locally sourced: site-specific immune barriers to metastasis.Nature reviews. Immunology · 2023Review
- Programmed cell death-1 receptor-mediated regulation of TbetProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours.Frontiers in pharmacology · 2023Article
- A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours.Frontiers in pharmacology · 2023Article
- The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice.Frontiers in immunology · 2023Article
- The unique role of innate lymphoid cells in cancer and the hepatic microenvironment.Cellular & molecular immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Type 2 innate lymphoid cells (ILC2) potentiate immune responses, however, their role in mediating adaptive immunity in cancer has not been assessed. Here, we report that mice genetically lacking ILC2s have significantly increased tumour growth rates and conspicuously higher frequency of circulating tumour cells (CTCs) and resulting metastasis to distal organs. Our data support the model that IL-33 dependent tumour-infiltrating ILC2s are mobilized from the lungs and other tissues through chemoattraction to enter tumours, and subsequently mediate tumour immune-surveillance by cooperating with dendritic cells to promote adaptive cytolytic T cell responses. We conclude that ILC2s play a fundamental, yet hitherto undescribed role in enhancing anti-cancer immunity and controlling tumour metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.